Ryvu Therapeutics announced the dosing of the first patient in the POTAMI-61 Phase II study, investigating RVU120, a novel small-molecule treatment for myelofibrosis. This study explores RVU120 as both a monotherapy and in combination with JAK inhibitors, targeting patients with unmet medical needs.
Company Information
Company
Ryvu Therapeutics
Location
Kraków, Lesser Poland Voivodeship, Poland
About
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on innovative small molecule therapies targeting emerging oncology challenges. The company is involved in advancing novel treatments to address significant unmet medical needs in cancer care. Ryvu's programs emphasize the development of drugs that can improve the outcomes for patients with hematologic malignancies and solid tumors. The company seeks to leverage strong preclinical and clinical data to maximize the potential of its therapeutic candidates.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ryvu Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
KrakówBiotechnologyHealth CareMedicalTherapeuticsPharmaceutical